Actively Recruiting
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Led by Taisho Pharmaceutical Co., Ltd. · Updated on 2026-01-09
24
Participants Needed
1
Research Sites
44 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment
CONDITIONS
Official Title
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Japanese males and females aged 18 to 75 years at consent
- Patients with chronic hepatic impairment classified as mild (Class A) or moderate (Class B) by Child-Pugh classification
- Subjects with normal hepatic function aged 18 to 75 years at consent
- Subjects with body mass index between 18.5 and less than 35 at screening
You will not qualify if you...
- History of liver resection or liver transplantation
- Grade II or higher hepatic encephalopathy
- Estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m2 for patients with hepatic impairment
- Current or past diseases that disqualify participation for subjects with normal hepatic function
- eGFR less than 60 mL/min/1.73 m2 for subjects with normal hepatic function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Actively Recruiting
Research Team
T
Taisho Pharmaceutical Co., Ltd.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here